非小细胞肺癌术后辅助靶向治疗

doi:10.3760/cma.j.cn371439-20191105-00010

国际肿瘤学杂志 ›› 2020, Vol. 47 ›› Issue (4): 240-243.doi: 10.3760/cma.j.cn371439-20191105-00010

非小细胞肺癌术后辅助靶向治疗

唐文洁^1,², 谢鹏²()

¹ 济南大学山东省医学科学院医学与生命科学学院,济南 250022
² 山东省肿瘤防治研究院(山东省肿瘤医院)放疗科,山东第一医科大学(山东省医学科学院),济南 250117

收稿日期:2019-11-05 修回日期:2019-11-11 出版日期:2020-04-08 发布日期:2020-05-26
通讯作者: 谢鹏 E-mail:xiepengro@126.com
基金资助:
国家自然科学基金(81502667);山东省重点研发计划(2016GSF201167)

Postoperative adjuvant targeted therapy for non-small cell lung cancer

Tang Wenjie^1,², Xie Peng²()

¹ School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan 250022, China
² Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250117, China

Received:2019-11-05 Revised:2019-11-11 Online:2020-04-08 Published:2020-05-26
Contact: Xie Peng E-mail:xiepengro@126.com
Supported by:
National Natural Science Foundation of China(81502667);Key Research and Development Plan of Shandong Province of China(2016GSF201167)

摘要/Abstract

摘要：

含铂双药化疗作为非小细胞肺癌(NSCLC)患者术后辅助治疗的主要手段之一,其临床疗效已达瓶颈,难以进一步改善患者生存。表皮生长因子受体(EGFR)酪氨酸激酶抑制剂目前已经成为EGFR敏感基因阳性晚期NSCLC患者的标准一线治疗,但其作为术后辅助治疗的价值目前尚不明确。近年国内外针对该领域开展了一些研究。

关键词: 癌,非小细胞肺, 分子靶向治疗, 肿瘤辅助疗法

Abstract:

As one of the main methods of postoperative adjuvant therapy for non-small cell lung cancer (NSCLC) patients, the clinical effect of platinum-containing dual-drug chemotherapy has reached a ceiling effect and it is difficult to further improve the survival of patients with NSCLC. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors have become the standard first-line treatment for advanced NSCLC with EGFR mutation, but its value as postoperative adjuvant therapy is far to be investigated. Some studies have been carried out in this field in recent years.

Key words: Carcinoma,non-small-cell lung, Molecular targeted therapy, Neoadjuvant therapy

唐文洁, 谢鹏. 非小细胞肺癌术后辅助靶向治疗[J]. 国际肿瘤学杂志, 2020, 47(4): 240-243.

Tang Wenjie, Xie Peng. Postoperative adjuvant targeted therapy for non-small cell lung cancer[J]. Journal of International Oncology, 2020, 47(4): 240-243.

参考文献 24

[1]	Bray F, Ferlay J, Soerjomataram I , et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492. doi: 10.3322/caac.v68.6
[2]	Chen W, Zheng R, Zeng H , et al. Annual report on status of cancer in China, 2011[J]. Chin J Cancer Res, 2015,27(1):2-12. DOI: 10.3978/j.issn.1000-9604.2015.01.06.
[3]	You R, Liu J, Wu DB , et al. Cost-effectiveness analysis of EGFR mutation testing and afatinib versus gemcitabine-cisplatin as first-line therapy for advanced non-small-cell lung cancer in China[J]. Cancer Manag Res, 2019,11:10239-10248. DOI: 10.2147/CMAR.S219722. doi: 10.2147/CMAR
[4]	Goffin J, Lacchetti C, Ellis PM , et al. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review[J]. J Thorac Oncol, 2010,5(2):260-274. DOI: 10.1097/JTO.0b013e3181c6f035. doi: 10.1097/JTO.0b013e3181c6f035
[5]	Ettinger DS, Wood DE, Akerley W , et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4. 2016[J]. J Natl Compr Canc Netw, 2016,14(3):255-264. DOI: 10.6004/jnccn.2016.0031. doi: 10.6004/jnccn.2016.0031
[6]	Wu YL, Zhou C, Hu CP , et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial[J]. Lancet Oncol, 2014,15(2):213-222. DOI: 10.1016/S1470-2045(13)70604-1. doi: 10.1016/S1470-2045(13)70604-1
[7]	Shi Y, Li J, Zhang S , et al. Molecular epidemiology of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology-mainland China subset analysis of the PIONEER study[J]. PLoS One, 2015,10(11):e0143515. DOI: 10.1371/journal.pone.0143515. doi: 10.1371/journal.pone.0143515
[8]	Kim C, Liu SV . First-line EGFR TKI therapy in non-small cell lung cancer: looking back before leaping forward[J]. Ann Oncol, 2019,30(12):1852-1855. DOI: 10.1093/annonc/mdz415. doi: 10.1093/annonc/mdz415
[9]	Goss GD, O'Callaghan C, Lorimer I, et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study[J]. J Clin Oncol, 2013,31(27):3320-3326. DOI: 10.1200/JCO.2013.51.1816. doi: 10.1200/JCO.2013.51.1816
[10]	Kelly K, Altorki NK, Eberhardt WE , et al. Adjuvant erlotinib versus placebo in patients with stage ⅠB-ⅢA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase Ⅲ trial[J]. J Clin Oncol, 2015,33(34):4007-4014. DOI: 10.1200/JCO.2015.61.8918. doi: 10.1200/JCO.2015.61.8918
[11]	Tsuboi M, Kato H, Nagai K , et al. Gefitinib in the adjuvant setting: safety results from a phase Ⅲ study in patients with completely resected non-small cell lung cancer[J]. Anticancer Drugs, 2005,16(10):1123-1128. DOI: 10.1097/00001813-200511000-00012. doi: 10.1097/00001813-200511000-00012
[12]	Wu YL, Herbst RS, Mann H , et al. ADAURA: phase Ⅲ, double-blind, randomized study of osimertinib versus placebo in EGFR mutation-positive early-stage NSCLC after complete surgical resection[J]. Clin Lung Cancer, 2018,19(4):e533-e536. DOI: 10.1016/j.cllc.2018.04.004. doi: 10.1016/j.cllc.2018.04.004
[13]	Janjigian YY, Park BJ, Zakowski MF , et al. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations[J]. J Thorac Oncol, 2011,6(3):569-575. DOI: 10.1097/JTO.0b013e318-202bffe. doi: 10.1097/JTO.0b013e318202bffe
[14]	Li N, Ou W, Ye X , et al. Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage ⅢA-N₂ non-small cell lung cancer harbouring EGFR mutations: a randomized, phase Ⅱ study[J]. Ann Surg Oncol, 2014,21(6):2091-2096. DOI: 10.1245/s10434-014-3586-9. doi: 10.1245/s10434-014-3586-9
[15]	Feng S, Wang Y, Cai K , et al. Randomized adjuvant chemotherapy of EGFR-mutated non-small cell lung cancer patients with or without icotinib consolidation therapy[J]. PLoS One, 2015,10(10):e0140794. DOI: 10.1371/journal.pone.0140794. doi: 10.1371/journal.pone.0140794
[16]	Pennell NA, Neal JW, Chaft JE , et al. SELECT: a phase Ⅱ trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small-cell lung cancer[J]. J Clin Oncol, 2019,37(2):97-104. DOI: 10.1200/JCO.18.00131.
[17]	Xie H, Wang H, Xu L , et al. Gefitinib versus adjuvant chemotherapy in patients with stage Ⅱ-ⅢA non-small-cell lung cancer harboring positive EGFR mutations: a single-center retrospective study[J]. Clin Lung Cancer, 2018,19(6):484-492. DOI: 10.1016/j.cllc.2018.05.007. doi: 10.1016/j.cllc.2018.05.007
[18]	Lv C, An C, Feng Q , et al. A retrospective study of stage Ⅰ to Ⅲa lung adenocarcinoma after resection: what is the optimal adjuvant modality for patients with an EGFR mutation?[J]. Clin Lung Cancer, 2015,16(6):e173-e181. DOI: 10.1016/j.cllc.2015.04.002. doi: 10.1016/j.cllc.2015.04.002
[19]	Zhong WZ, Wang Q, Mao WM , et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage Ⅱ-ⅢA (N₁-N₂) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study[J]. Lancet Oncol, 2018,19(1):139-148. DOI: 10.1016/S1470-2045(17)30729-5. doi: 10.1016/S1470-2045(17)30729-5
[20]	Yue D, Xu S, Wang Q , et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage ⅢA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial[J]. Lancet Respir Med, 2018,6(11):863-873. DOI: 10.1016/S2213-2600(18)30277-7.
[21]	Uramoto H, Shimokawa H, Hanagiri T , et al. Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma[J]. Lung Cancer, 2011,73(3):361-365. DOI: 10.1016/j.lungcan.2011.01.008.
[22]	Liu D, Yang Y, Zhao S . Autophagy facilitates the EGFR-TKI acquired resistance of non-small-cell lung cancer cells[J]. J Formos Med Assoc, 2014,113(3):141-142. DOI: 10.1016/j.jfma.2012.10.017.
[23]	Westover D, Zugazagoitia J, Cho BC , et al. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors[J]. Ann Oncol, 2018,29(suppl_1):i10-i19. DOI: 10.1093/annonc/mdx703.
[24]	Hsu WH, Yang JC, Mok TS , et al. Overview of current systemic management of EGFR-mutant NSCLC[J]. Ann Oncol, 2018,29(suppl_1):i3-i9. DOI: 10.1093/annonc/mdx702.

非小细胞肺癌术后辅助靶向治疗

Postoperative adjuvant targeted therapy for non-small cell lung cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 24

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[5]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安. 新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[6]	马正红, 姜超. 非小细胞肺癌KRAS^G12C突变的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 95-98.
[7]	黄辉, 丁江华. 靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[8]	李开春, 丁昌利, 于文艳. 安罗替尼联合特瑞普利单抗治疗晚期肺肉瘤样癌1例[J]. 国际肿瘤学杂志, 2023, 50(8): 511-512.
[9]	陈秋, 王雷, 王明琦, 张梅. 恩沃利单抗联合阿昔替尼治疗肾癌肺转移1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(7): 445-448.
[10]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[11]	刘利, 朱思齐, 孙梦颖, 何敬东. PARP抑制剂在小细胞肺癌靶向治疗中的进展[J]. 国际肿瘤学杂志, 2023, 50(6): 368-372.
[12]	刘博翰, 黄俊星. 溶质载体SLC7A5及SLC7A11基因在恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 280-284.
[13]	徐放, 朱文钿. 肝细胞癌合并微血管侵犯术后辅助治疗现状[J]. 国际肿瘤学杂志, 2023, 50(5): 304-309.
[14]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[15]	邓莉莉, 段星宇, 李保中. HER2靶向药物及其联合治疗方案在胃及食管胃结合部腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(12): 751-757.